For example, TRIM56 has been shown to delay NAFLD progression by ubiquitination modification of the key protein for fatty acid synthesis, FASN, but this study is mainly based on animal models and in vitro experiments, and has not yet delved into the existence of relevant mutations or expression differences in patients. Here, TRIM56 is linked to metabolic dysfunction-associated steatotic liver disease.